A Global Real-World Evidence Study on the Effectiveness and Safety/Tolerability of Foslevodopa/Foscarbidopa in Patients Earlier Within Advanced Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how effective Foslevodopa/Foscarbidopa is in treating adult participants earlier within advanced Parkinson disease under routine clinical practice. Foslevodopa/Foscarbidopa is an approved drug for the treatment of Parkinson's Disease. Approximately 100 adult participants who are prescribed Foslevodopa/Foscarbidopa by their doctors will be enrolled across approximately 40 sites across the world. Participants will receive Foslevodopa/Foscarbidopa subcutaneous infusion as prescribed by their physician. Participants will be followed for up to 6 months. There are no additional examinations due to the study but the participants and caregivers will need to fill several questionnaires to generate data on their motor function and well-being
• Eligibility for Foslevodopa/Foscarbidopa (LDp/CDp) therapy in accordance with approved local label in the participating country and local reimbursement regulations, if applicable
• A diagnosis of levodopa-responsive idiopathic Parkinson's Disease (PD)
• Adult male or female between 18 and 80 years of age
• Disease duration (time since diagnosis) \<10 years
• Time since motor fluctuations ≤3 years
• H\&Y Stage \<3 in best on
• off time of 2.5-6 hours per day
• Naïve to LDp/CDp
• Treatment has been optimized with oral/transdermal PD medication in the opinion of the Investigator
• Decision to treat with LDp/CDp made by the clinician prior to any decision to approach the participant to participate in the study
• Willing and able to comply with procedures required during this study, specifically with entering data and filling questionnaires in an electronic device (tablet).
• Prior to any study-related procedures being performed, the participant or Legal Authorized Representative (LAR) must voluntarily sign an Authorization for Use/Disclosure of Data (AUDD)/Informed Consent Form (ICF) according to national regulations once the study has been explained and the participant has the opportunity to have any questions answered